Drugs / Simmitecan
Simmitecan
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02870036 | Oct 2016 → Dec 2020 | colorectal cancer | Haihe Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01832298 | Dec 2012 → Mar 2016 | neoplasm | Haihe Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Simmitecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01832298 ↗ |
| Known as | Simmitecan hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL4301491 ↗ |
| Known as | Simmitecan Hydrochloride for Injection | “Drug: Simmitecan Hydrochloride for Injection” NCT01832298 ↗ |
| Action | Inhibit | “inhibiting topoisomerase I” NCT01832298 ↗ |
| Modality | Small molecule | “Simmitecan is an anticancer ester prodrug” NCT01832298 ↗ |
| Route | Intravenous | “for i.v.90 minutes” NCT01832298 ↗ |